VJOncology is committed to improving our service to you

HOPA 2018 | Can checkpoint inhibitors combinations replace single agent drugs?

VJOncology is committed to improving our service to you

Christopher Campen

In this interview, Christopher Campen, PharmD, BCOP, from the GHS Cancer Institute, Greenville, SC, discusses combining immune checkpoint inhibitors for the treatment of cancer as opposed to using single agent drugs, but do the benefits outweigh the risks? Checkpoint inhibitors can be associated with severe side effects such as dermatitis, but despite this, the correct management of these adverse effects may lead to increased survival rates compared to current methods of treatment. This video was recorded at the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference held in Denver, CO.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter